GSK has received approval from the US Food and Drug Administration (FDA) for the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy, for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 49 who are at increased risk.

Arexvy was previously approved for use in adults aged 60 years and older, and later for individuals aged 50 to 59 who are at increased risk of RSV-related lower respiratory tract disease.

With this expanded approval, the vaccine can now be administered to a broader adult population considered at higher risk of severe RSV infection.

Arexvy is an adjuvanted RSV vaccine developed by GSK to prevent lower respiratory tract disease caused by respiratory syncytial virus. The vaccine was first approved by the US FDA in 2023 for use in older adults.

The latest regulatory approval expands the indicated patient population eligible to receive the vaccine in the United States.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!